Status:
COMPLETED
CX3CR1+T Cell Predict Immunotherapy Efficacy
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to evaluate the correlation between the proportion of flow-sorted CX3CR1+T cells in peripheral blood and the CX3CR1+T-specific gene signature and the efficacy of immunotherapy.
Detailed Description
The status and abundance of T cells vary across tumor microenvironments (TMEs) may fundamentally influence response to immunotherapy in non-small cell lung cancer. CX3CR1+ CD8+ T cells showed high mig...
Eligibility Criteria
Inclusion
- At least 18 years old;
- Diagnosed as Non-small cell lung cancer by biopsy before treatment;
- Prepare to receive PD(L)1 inhibitor monotherapy or combined chemotherapy and antivascular drugs;
- Lesion imaging can be measured and evaluated by RECIST1.1 standard;
- Life expectancy exceeds 3 months;
- ECOG score 0-2;
- The newly IO treated patients did not receive immunotherapy, chemoradiotherapy before participate in the trial;
- Sign informed consent and be willing to provide 5ml of peripheral blood for research
Exclusion
- Genetic test showed EGFR and ALK mutations;
- Patients with other co-morbidities that may affect their follow-up and short-term survival;
- Patients with any history of antitumor therapy;
- Patients with a history of other systemic tumors;
- The ineligible participants assessed by the researchers
Key Trial Info
Start Date :
April 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06054152
Start Date
April 10 2023
End Date
June 20 2025
Last Update
June 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan cancer hospital
Changsha, Hunan, China
2
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China